Education
About Us
Working with TipRanks
Follow Us
Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
LTRN Stock Chart & Stats
$3.02
$0.04(1.09%)
At close: 4:00 PM EST
$3.02
$0.04(1.09%)
Day’s Range― - ―
52-Week Range$2.53 - $5.74
Previous CloseN/A
Volume32.66K
Average Volume (3M)51.93K
Market Cap
$30.20M
Enterprise Value$21.90M
Total Cash (Recent Filing)$12.36M
Total Debt (Recent Filing)$93.95K
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Mar 05, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding11,184,423
10 Day Avg. Volume53,554
30 Day Avg. Volume51,928
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.62
Price to Sales (P/S)0.00
P/FCF Ratio-1.93
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-365.65
Enterprise Value/Ebitda-1.13
Forecast
1Y Price Target
$25.00Price Target Upside727.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Validation (LP-184 Phase Ia)Achieving all primary endpoints with a 48% clinical benefit rate materially de-risks LP-184 relative to early-stage peers. Durable impact: positive human efficacy signals improve prospects for later-stage trials, partnering interest, and regulatory engagement, raising program success probability.
RADR AI Platform Commercial ReadinessA commercially ready, modular AI platform creates a structural advantage by enabling licensing, services, and partnerships that can generate recurring non-drug revenue. Over months, platform monetization can diversify cash sources and enhance trial efficiency and target selection.
Low Financial Leverage Reduces Solvency RiskVery low debt limits fixed obligations and preserves optionality on timing and structure of future financings or partnerships. Structurally, low leverage reduces bankruptcy risk and gives management flexibility to pursue clinical or platform milestones without debt-driven constraints.
Bears Say
Pre-revenue With Persistent Net LossesRemaining pre-revenue means Lantern lacks product-derived cash flow and must fund operations externally. Persistently large net losses imply continued financing dependence, constrain reinvestment capacity, and lengthen the time to sustainable margins or self-funding business model.
Heavy Cash Burn And Limited RunwaySustained negative operating cash flow and limited cash to Q3 2026 create a structural funding cliff. This forces near-term capital raises that can dilute shareholders, limit the company's ability to run multiple trials, and compress optionality for partnering or commercialization pacing.
Shrinking Equity Base Increases Financing RiskA materially reduced equity base signals repeated financing or valuation erosion, leaving less balance-sheet cushion for future adverse outcomes. Structurally this elevates dilution risk, constrains negotiating leverage with partners, and raises the stakes of near-term clinical and funding milestones.
Lantern Pharma News
LTRN FAQ
What was Lantern Pharma, Inc.’s price range in the past 12 months?
Lantern Pharma, Inc. lowest stock price was $2.53 and its highest was $5.74 in the past 12 months.
What is Lantern Pharma, Inc.’s market cap?
Lantern Pharma, Inc.’s market cap is $30.20M.
When is Lantern Pharma, Inc.’s upcoming earnings report date?
Lantern Pharma, Inc.’s upcoming earnings report date is Mar 05, 2026 which is in 17 days.
How were Lantern Pharma, Inc.’s earnings last quarter?
Lantern Pharma, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.47 by $0.08.
Is Lantern Pharma, Inc. overvalued?
According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Undervalued.
Does Lantern Pharma, Inc. pay dividends?
Lantern Pharma, Inc. does not currently pay dividends.
What is Lantern Pharma, Inc.’s EPS estimate?
Lantern Pharma, Inc.’s EPS estimate is -0.46.
How many shares outstanding does Lantern Pharma, Inc. have?
Lantern Pharma, Inc. has 11,184,423 shares outstanding.
What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?
Lantern Pharma, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.47. Following the earnings report the stock price went down -0.575%.
Which hedge fund is a major shareholder of Lantern Pharma, Inc.?
Currently, no hedge funds are holding shares in LTRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantern Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (727.81% Upside)
$25.00 (727.81% Upside)
Hedge Fund Trend
Decreased
By 10.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.09%
12-Months-Change
Fundamentals
Return on Equity
-104.58%
Trailing 12-Months
Asset Growth
-55.02%
Trailing 12-Months
Company Description
Lantern Pharma, Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
LTRN Company Deck
LTRN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical trial results and regulatory progress, along with advancements in AI platform commercialization. Financial stability was noted, but there is a requirement for additional funding in the near future.View all LTRN earnings summariesLTRN Stock 12 Month Forecast
Average Price Target
$25.00
▲(727.81% Upside)
Technical Analysis
Ownership Overview
19.24% Insiders
3.85% Mutual Funds
11.96% Other Institutional Investors
61.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---